Search Results for "bortezomib"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for bortezomib. Results 1 to 3 of 3 total matches.
See also: Velcade

Isatuximab (Sarclisa) for Multiple Myeloma (online only)

   
The Medical Letter on Drugs and Therapeutics • Dec 09, 2024  (Issue 1717)
. Patients were randomized to receive isatuximab in addition to standard treatment (bortezomib ...
Isatuximab-irfc (Sarclisa – Sanofi), a CD38-directed cytolytic antibody, has been approved by the FDA for treatment of newly diagnosed multiple myeloma in adults who are not eligible for autologous stem cell transplantation (ASCT). The drug was approved earlier for treatment of relapsed or treatment-refractory multiple myeloma.
Med Lett Drugs Ther. 2024 Dec 9;66(1717):e200-1   doi:10.58347/tml.2024.1717e |  Show IntroductionHide Introduction

Caplacizumab (Cablivi) for iTTP

   
The Medical Letter on Drugs and Therapeutics • Oct 19, 2020  (Issue 1609)
Vincristine, cyclophosphamide, cyclosporine, and bortezomib have also been used, but large randomized trials ...
Caplacizumab-yhdp (Cablivi – Sanofi /Genzyme), a von Willebrand factor-directed antibody fragment, has been approved by the FDA for use in combination with plasma exchange and immunosuppressive therapy for treatment of immune-mediated thrombotic thrombocytopenic purpura (iTTP; formerly called acquired thrombotic thrombocytopenic purpura [aTTP]) in adults. It is the first drug to be approved in the US for this indication.
Med Lett Drugs Ther. 2020 Oct 19;62(1609):163-4 |  Show IntroductionHide Introduction

Table: Inhibitors and Inducers of CYP Enzymes, P-Glycoprotein, and Other Transporters (online only)

   
The Medical Letter on Drugs and Therapeutics • Feb 06, 2023  (Issue 1669)
delavirdine fluconazole fluvoxamine ticlopidine abiraterone armodafinil bortezomib cannabidiol ...
View the Inhibitors and Inducers of CYP Enzymes, P-Glycoprotein, and Other Transporters tables
Med Lett Drugs Ther. 2023 Feb 6;65(1669):e28-30   doi:10.58347/tml.2023.1669g |  Show IntroductionHide Introduction